AZYO Aziyo Biologics

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

The conference call can be accessed using the following information:

Webcast:

U.S. Investors: 877-407-8029

International Investors: 201-689-8029

Conference ID: 13751810

Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners



EN
20/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results o...

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025 SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed usin...

 PRESS RELEASE

Elutia Announces $15.0 Million Registered Direct Offering

Elutia Announces $15.0 Million Registered Direct Offering SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company’s Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purchase up to 480,000 shares of the Company’s Class A common stock at a purchase price of $2.499 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exerc...

 PRESS RELEASE

Elutia Announces Full Launch of EluPro™ Following Strong Initial Deman...

Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. “EluPro is an exciting innovation that addresses tw...

 PRESS RELEASE

Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcin...

Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners SILVER SPRING, Md., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Vizient for the benefit of Southern Strategic Sourcing Partners (S3P), to provide access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope to S3P’s extensive network of 993 acute care facilities, starting immediately. EluPro is the world’s first and only antibiotic-eluting biologic envelope ...

 PRESS RELEASE

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premie...

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc. SILVER SPRING, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced it has been awarded a national group purchasing agreement for Cardiac Rhythm Management Devices with Premier, Inc. Effective November 15, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the EluPro™ Antibiotic-Eluting BioEnvelope. “We are thrilled to br...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch